Acute Coronary Syndrome Subphenotypes Based on Repeated Biomarker Measurements in Relation to Long-Term Mortality Risk.

"specifically both a random intercept and slope were modeled as random effects in the linear mixed-effects models (data s1 ) using sampling time during follow-up as the time scale for slope.; data s1 table s1 figures s1-s5"

"Disclosures M de Bakker is supported by the Jaap Schouten Foundation. Dr Scholte is supported by a grant from the Dutch Research Council (NWO), grant number 628.011.214 (STRAP). Dr Asselbergs is supported by UCL Hospitals NIHR Biomedical Research Centre. The remaining authors have no disclosures to report."

"Sources of Funding Roche Diagnostics provided assays and kits in support of this work. COBAS C, COBAS E, and ELECSYS are trademarks of Roche. The BIOMArCS study was supported and funded by The Netherlands Heart Foundation, grant number 2007B012 (Utrecht, The Netherlands), The Netherlands Heart Institute–Interuniversity Cardiology Institute of Netherlands, project number 071.01 (Utrecht, The Netherlands), and the Working Group of Cardiovascular Research Netherlands, all of which are noncommercial funding bodies. An unrestricted research grant was further obtained from Eli Lilly, the Netherlands."

"BIOMArCS was conducted in compliance with the Declaration of Helsinki, and the study protocol was approved by the institutional review boards of the participating hospitals. All study subjects provided written informed consent. BIOMArCS is registered in The Netherlands Trial Register with the unique identifiers NTR1106 and NTR1698."